A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris

A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris

Bibliographic Details
Main Authors:	Kazuki Yatsuzuka, Masamoto Murakami
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Journal of Cutaneous Immunology and Allergy
Online Access:	https://doi.org/10.1002/cia2.12284

Similar Items

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022-08-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024-12-01)

Tildrakizumab in Psoriasis and Beyond
by: Aditya K. Bubna, et al.
Published: (2024-07-01)

A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab
by: Kristian Garn Du Jardin, et al.
Published: (2020-07-01)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
by: Thomas Damsin
Published: (2023-06-01)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024-07-01)

Guselkumab for the treatment of psoriasis – evidence to date
by: Miguel Nogueira, et al.
Published: (2019-07-01)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023-09-01)

Successful guselkumab treatment of a refractory psoriasis patient with Graves’ disease: a case report
by: Xinyi Shao, et al.
Published: (2024-04-01)

Plantar pustules in a psoriasis patient during the guselkumab therapy
by: Shinsuke Nakazawa, et al.
Published: (2021-10-01)

A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
by: Martina Burlando, et al.
Published: (2024-08-01)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023-03-01)

Comments about the comparative bulk RNA sequencing between palmoplantar pustulosis and dyshidrotic palmoplantar eczema [version 1; peer review: 2 approved]
by: Masamoto Murakami, et al.
Published: (2024-12-01)

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
by: Eugenia Veronica Di Brizzi, et al.
Published: (2023-10-01)

Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
by: Francisco José Rodríguez-Cuadrado, et al.
Published: (2024-09-01)

Successful treatment of pyoderma gangrenosum with guselkumab
by: Sofia Botvid, et al.
Published: (2025-03-01)

Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
by: Nicoletta Bernardini, et al.
Published: (2022-10-01)

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome
by: Simge Ünal, et al.
Published: (2024-06-01)

Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series
by: Marco Galluzzo, et al.
Published: (2024-02-01)

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
by: Julia-Tatjana Maul, et al.
Published: (2024-11-01)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022-07-01)

Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report
by: Alex Nguyen, et al.
Published: (2023-06-01)

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs
by: Viviana Lora, et al.
Published: (2024-11-01)

Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review
by: Esperanza Welsh, et al.
Published: (2024-04-01)

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
by: Tiago Torres, et al.
Published: (2024-03-01)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023-09-01)

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024-10-01)

Can Biologic Agents Improve Treatment Success in Obese Patients With Psoriasis Vulgaris: A Retrospective Review of 320 Patients With Psoriasis Vulgaris
by: Atıl Avcı, et al.
Published: (2024-01-01)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024-03-01)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024-02-01)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023-02-01)

Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris
by: Mai Nishimura, et al.
Published: (2022-10-01)

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis
by: Paolo Dapavo, et al.
Published: (2024-08-01)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01)

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
by: Megna M, et al.
Published: (2024-05-01)

Clinically and radiologically successful treatment of spondylitis by guselkumab in a patient with pustulotic arthro‐osteitis
by: Natsumi Ikumi, et al.
Published: (2023-08-01)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?
by: Eugenia Veronica Di Brizzi, et al.
Published: (2024-10-01)

Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis
by: Tina Bhutani, et al.
Published: (2024-04-01)